China Resources Pharmaceutical Group Limited (3320.HK)
HKD 5.29
(0.0%)
HKD 5.29
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.85 Billion HKD | 10.11% |
| 2022 | 3.5 Billion HKD | 13.62% |
| 2021 | 3.08 Billion HKD | 10.87% |
| 2020 | 2.77 Billion HKD | -15.45% |
| 2019 | 3.28 Billion HKD | -18.61% |
| 2018 | 4.03 Billion HKD | 15.93% |
| 2017 | 3.48 Billion HKD | 23.45% |
| 2016 | 2.82 Billion HKD | -1.01% |
| 2015 | 2.85 Billion HKD | 7.72% |
| 2014 | 2.64 Billion HKD | 0.24% |
| 2013 | 2.63 Billion HKD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 2.82 Billion HKD | 0.0% |
| 2023 Q4 | 1.2 Billion HKD | 0.0% |
| 2023 FY | 3.85 Billion HKD | 10.11% |
| 2023 Q2 | 3.03 Billion HKD | 0.0% |
| 2022 Q2 | 3.02 Billion HKD | 0.0% |
| 2022 FY | 3.5 Billion HKD | 13.62% |
| 2022 Q4 | 1.12 Billion HKD | 0.0% |
| 2021 Q2 | 2.43 Billion HKD | 0.0% |
| 2021 Q4 | 1.33 Billion HKD | 0.0% |
| 2021 FY | 3.08 Billion HKD | 10.87% |
| 2020 FY | 2.77 Billion HKD | -15.45% |
| 2020 Q4 | 719.93 Million HKD | 0.0% |
| 2020 Q2 | 2.57 Billion HKD | 0.0% |
| 2019 Q2 | 3.03 Billion HKD | 0.0% |
| 2019 FY | 3.28 Billion HKD | -18.61% |
| 2019 Q4 | 251.04 Million HKD | 0.0% |
| 2018 FY | 4.03 Billion HKD | 15.93% |
| 2018 Q2 | 2.24 Billion HKD | 0.0% |
| 2018 Q4 | 1.72 Billion HKD | 0.0% |
| 2017 FY | 3.48 Billion HKD | 23.45% |
| 2017 Q2 | 1.81 Billion HKD | 0.0% |
| 2017 Q4 | 1.67 Billion HKD | 0.0% |
| 2016 FY | 2.82 Billion HKD | -1.01% |
| 2016 Q4 | 1.18 Billion HKD | 0.0% |
| 2016 Q2 | 1.63 Billion HKD | 0.0% |
| 2015 Q2 | 2.28 Billion HKD | 0.0% |
| 2015 FY | 2.85 Billion HKD | 7.72% |
| 2015 Q4 | 568.41 Million HKD | 0.0% |
| 2014 Q4 | 1.52 Billion HKD | 10.75% |
| 2014 Q3 | 1.37 Billion HKD | 0.0% |
| 2014 Q2 | 1.37 Billion HKD | 0.0% |
| 2014 Q1 | 1.37 Billion HKD | 0.0% |
| 2014 FY | 2.64 Billion HKD | 0.24% |
| 2013 Q3 | 1.36 Billion HKD | 0.0% |
| 2013 FY | 2.63 Billion HKD | 0.0% |
| 2013 Q2 | 1.36 Billion HKD | 0.0% |
| 2013 Q1 | 1.36 Billion HKD | 0.0% |
| 2013 Q4 | 1.37 Billion HKD | 0.68% |
| 2012 Q4 | 1.36 Billion HKD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | -3569.349% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | -105.013% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 2465.309% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | 25199.29% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | 7412.868% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | -22982.088% |
| Essex Bio-Technology Limited | 275.25 Million HKD | -1300.222% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | 13462.851% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 3733.306% |
| SSY Group Limited | 1.31 Billion HKD | -192.295% |
| JBM (Healthcare) Limited | 130.46 Million HKD | -2854.284% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | -1343.711% |